Dermiglow
Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy and Skin Radiance-enhancing Effect of Dermial®.
Sponsor study identifier
interventional
146
1 country
1
Study Start
August 5, 2026
Actual (reported)Primary Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The present clinical study has been designed to evaluate the efficacy and safety of Dermial® at a daily dose of 60 mg on skin brightness, hydration, luminosity and other signs of facial skin aging in healthy women aged 35 to 65 years presenting physiological age-related skin aging, compared with placebo over a 12-week supplementation period.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 30, 2026
Actual (reported)August 5, 2026
Actual (reported)August 27, 2026
Actual (reported)March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in Facial Skin Glow
Facial skin gloss will be measured at the right periocular area using the Skin-Glossymeter® GL 200 probe. Skin gloss values will be expressed in arbitrary units (AU), with a measurement range of 0 to 100 AU. Results will be reported as the mean change from baseline to Week 12. Higher values indicate greater skin gloss.
Baseline (week 0) to week 12 (primary analysis at week 12; assessments at weeks 3, 6 and 12)
Change in Skin Glow at Additional Facial Areas
Baseline (week 0) to week 12 (assessments at weeks 3, 6 and 12)
Change in Facial Skin Radiance
Baseline (week 0) to week 12 (assessments at weeks 3, 6 and 12)
Hyaluronic acid matrix ingredien
Placebo
1 cap 60 mg/day
Placebo
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Institute of Advanced Medicine and Dermatology (IMDA)
Madrid, Madrid, 28001, Spain
First Submitted
July 30, 2026
First Posted
August 27, 2026
Study Start
August 5, 2026
Actual (reported)Primary Completion
March 31, 2028
EstimatedPharmacokinetic (PK) Study of Phytochemicals in Whole Grains (WGs)- Corn
Change in Facial Stratum Corneum Hydration
Baseline (week 0) to week 12 (assessments at weeks 3, 6 and 12)
Change in Facial Skin pH
Baseline (week 0) to week 12 (assessments at weeks 3, 6 and 12)
Mean Change From Baseline in Facial Wrinkle (SEw)
Baseline (week 0) to week 12 (assessments at weeks 3, 6 and 12)
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 18, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: